Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience

Abstract

These results demonstrate that under proper conditions, treatment discontinuation is feasible outside of clinical trial setting. MR^4.5 duration of 6 years or more before discontinuation is associated with very low risk of loss of MR^4.5.